Assessing the Impact of Timing and Coverage of United States COVID-19 Vaccination Campaigns: A Multi-Model Approach
Nande, A.; Larsen, S. L.; Turtle, J.; Davis, J. T.; Bandekar, S. R.; Lewis, B.; Chen, S.; Contamin, L.; Jung, S.-m.; Howerton, E.; Shea, K.; Bay, C.; Ben-Nun, M.; Bi, K.; Bouchnita, A.; Chen, J.; Chinazzi, M.; Fox, S. J.; Hill, A. L.; Hochheiser, H.; Lemaitre, J. C.; Loo, S. L.; Marathe, M.; Meyers, L. A.; Pearson, C. A. B.; Porebski, P.; Przykucki, E.; Smith, C. P.; Venkatramanan, S.; Vespignani, A.; Willard, T. C.; Yan, K.; Viboud, C.; Lessler, J.; Truelove, S.
Show abstract
Background Six years after its emergence, SARS-CoV-2 continues to have a substantial burden. The impact of vaccination and the optimal timing of its rollout remain uncertain given existing population immunity and variability in outbreak timing between summer and winter. Methods The US Scenario Modeling Hub convened its 19th round of ensemble projections for COVID-19 hospitalizations and deaths in the United States, where eight teams projected trajectories in each US state and nationally from April 2025 to April 2026 under five scenarios regarding vaccine recommendations and timing. Recommendations had two eligibility scenarios (high-risk individuals only and all-eligible) and two timing scenarios (classic start: mid-August, earlier start: late June). These were crossed to create four scenarios and were compared against a counterfactual scenario with no vaccination. Findings Compared to no vaccination, our ensemble projections estimated 90,000 (95% PI 53,000-126,000) hospitalizations averted in the high-risk and classic timing scenario across the US. Expanding to all-eligible age-groups averted an additional 26,000 (95% PI 14,000-39,000) hospitalizations, which when coupled with the early vaccination timing, was projected to further reduce national hospitalizations by 15,000 (95% PI -3,000-33,000). The majority of teams projected both summer and winter waves. Implications We project COVID-19 will cause significant hospitalizations and deaths in the US in the 2025-26 season and estimate significant benefits from a broad all-eligible vaccination recommendation. The results also suggest an additional benefit is likely to be gained from an earlier vaccination campaign. Funding Centers for Disease Control and Prevention; National Institute of Health (US), National Science Foundation (US)
Matching journals
The top 5 journals account for 50% of the predicted probability mass.